Introduction {#Sec1}
============

Small-for-size syndrome (SFSS) injury is a major concern after living donor liver transplantation (LDLT) \[[@CR1]\]. It manifests as coagulopathy, encephalopathy, intractable ascites, and prolonged jaundice \[[@CR2]\]. SFSS may cause prolonged hospitalization and graft loss, and thus, survival rates of patients with small-for-size grafts are worse than those with adequate graft size \[[@CR3]\].

SFSS is frequently encountered in small grafts, i.e., grafts with a graft weight- ratio below 0.8%, but may also be found in recipients of larger grafts \[[@CR1], [@CR4]\]. The initial mechanism of injury seems to be a hyperdynamic portal flow through a small liver graft, leading to excessive shear stress injury of sinusoidal cells \[[@CR5]\]. Consequently, early attempts to avert SFSS in small grafts focused on the diversion or reduction of portal inflow, such as splenic artery ligation \[[@CR6]\], splenectomy \[[@CR7], [@CR8]\], mesocaval shunt \[[@CR9]\], or partial portocaval shunt \[[@CR8], [@CR10], [@CR11]\]. But Fan and colleagues also suggest that a pivotal factor may also be a venous outflow of the graft, because "in the absence of uniform and adequate outflow, the inflow impedance, graft hypoperfusion, and therefore, portal hypertension are aggravated" \[[@CR1]\]. Hence, in patients with outflow obstruction, portal hypertension rather reflects outflow obstruction and is not the cause of graft injury. It follows that in this situation, it may even be deleterious to mitigate portal pressure because it may reduce adequate portal flow that is also necessary for graft regeneration \[[@CR12], [@CR13]\]. Additionally, Boillot, who was one of the first to describe and widely adapt portal decompression to avoid SFSS, has retracted from advocating it in the general situation, because it may cause insufficient portal inflow and subsequent graft failure \[[@CR14]\].

To address possible outflow obstruction in right liver grafts, Fan and colleagues \[[@CR1]\] advocate anterior incision of the inferior vena cava (IVC) to enlarge the orifice of the right hepatic vein (RHV) and prevent outflow obstruction of the RHV (Fig. [1](#Fig1){ref-type="fig"}). But small grafts may also tilt laterodorsal into a large abdominal cavity, and this may lead to functional stenosis by choking on the outflow tract (Fig. [2](#Fig2){ref-type="fig"}). Therefore, we enlarged the orifice of the RHV by oval excision of the posterior sector of the orifice (Fig. [3](#Fig3){ref-type="fig"}) and compared our new technique of posterior cavoplasty to conventional end-to-end anastomosis of the RHV in a test-of-concept study. Fig. 1Anterior cavoplasty (adapted from \[[@CR1]\]). **a** The transverse incision line at the anterior sector of the orifice of the right hepatic vein (RHV) is marked in red. **b** Orifice has been incised and trimmed to create an anterior enlargement of the venous outflow tractFig. 2In case of donor--recipient size mismatch, the small graft may tilt dorsolateral into the large abdominal cavity, and a ridge may develop at the posterior wall of the orifice of the RHVFig. 3Posterior cavoplasty by oval excision of the posterior sector of the orifice of the RHV. The anterior rim of the orifice of the MHV is left and also used for the anastomosis to avoid tension

Methods {#Sec2}
=======

The study included 22 adult patients who underwent LDLT of the right hepatic lobe between March 2000 and May 2007, of which seven patients were allocated to the control group and 15 patients to the experimental group that received the new posterior cavoplasty. The first 14 patients underwent systematic allocation by alternate assignment to one of the two study groups in the sequence of their transplantation (pseudo-randomization). After the first interim analysis, there were strong indicators that patients receiving posterior cavoplasty had better clinical outcome, and we decided to allocate all further patients to the experimental group for ethical reasons. Sample size calculations showed that 1:2 allocations would not significantly increase the type II error while retaining the type I error at the predefined level.

The patients (6 females and 16 males) had a median age of 46 (interquartile range (IQR) 41--54), a median body mass index of 24.7 kg/m2 (IQR 22.2--26.5), and a median graft-to-recipient weight ratio (percentage of recipient body weight) of 0.94% (IQR 0.83--1.1). Indication for liver transplantation included primary cancer of the liver (six patients), alcoholic liver disease (five patients), hepatitis B or C virus-related cirrhosis (five patients), cryptogenic cirrhosis (three patients), primary biliary cirrhosis (two patients), and acute-on-chronic autoimmune hepatitis (one patient). Most patients were severely ill, but some were transplanted primarily due to malignancy without reduced liver function (11 patients Child-Pugh class C, 3 patients class B, and 8 patients class A).

Portal pressure was measured after exposure of the hepatoduodenal ligament by insertion of a 22-gauge needle into the portal vein. PVP and central vein pressure (CVP) were measured at the same time in millimeter of mercury (mmHg). After LDLT, PVP, and CVP were measured again in the same fashion just before abdominal closure. Graft function was assessed by daily measurements of total bilirubin, alanine (ALT), and aspartate transaminase (AST), gamma-glutamyl transferase (GGT), and prothrombin time (PT) in a standardized fashion. Measurements were taken from 24 h prior to LDLT until one of the following endpoints was reached: end of the predefined study time (20 days), discharge from hospital, re-transplantation, or death of the patient. For diagnosis of SFSS, the following criteria were used: prolonged hyperbilirubinemia (above 10 mg/dl at POD 14), no signs for biliary duct obstruction and no proof of rejection, therapy refractory ascites, coagulopathy (INR \> 1.5).

Surgery {#Sec3}
-------

In the patients allocated to the control group, the anastomosis of the graft hepatic vein was performed in an end-to-end fashion to the stump of the RHV of the recipient. In the experimental group, the posterior wall of the orifice of the RHV was excised 5 mm in transverse and longitudinal axis, resulting in a laterodorsal position of the caval anastomosis (Fig. [3](#Fig3){ref-type="fig"}). Note also that the anterior sector of the cuff of the RHV is not trimmed completely to allow for hypertrophy of the graft without tension at the anastomosis. The RHV is anastomosed to the orifice with a running 5-0 vascular suture. Venoplasty of the grafts RHV was not necessary as all anastomoses could be sewn without tension. In the experimental group, only tributaries to the middle hepatic vein larger than 5-mm diameter were reconstructed, whereas, also smaller tributaries were reconstructed in the control group to avoid congestion of the right paramedian sector \[[@CR15]\]. The recipient middle and left hepatic veins were oversewn. The portal vein was anastomosed in typical end-to-end fashion, and the branch patch technique was used for anastomosis of the hepatic artery whenever possible. In all patients, an end-to-end anastomosis of the common bile duct was created.

Immunosuppression {#Sec4}
-----------------

At the time of transplantation, all patients received induction immunosuppression with 500-mg methylprednisolone and 20-mg basiliximab, the latter was repeated on the fourth postoperative day (POD). Immunosuppression was maintained with oral mycophenolat mofetil from the first POD at 1 g every 12 h and oral prednisolone with an initial daily dose of 75 mg per day. The latter was tapered by 5 mg and later 2.5 mg every 2 days to a maintenance dose of 7.5 mg per day. On the fifth POD, oral tacrolimus was added to the immunosuppressive regimen starting at 0.5 mg on the first day and increasing daily dose by 1--2 mg to achieve trough plasma level of 4--10 μg per liter.

Statistical analysis {#Sec5}
--------------------

All statistical calculations were carried out in the R language and environment for statistical computing (version 2.11.0) with type I error fixed at 0.05. The clinical characteristics of the two groups were represented as frequencies and percentages for categorial variables and median and interquartile range (IQR) for continuous variables. For univariate statistical inference, we used Fisher\'s exact test for categorial variables \[[@CR16]\] and the non-parametric Mann--Whitney *U* test for continuous variables \[[@CR17]\]. For multivariate analysis, we used ordinary least squares method or linear mixed effects models (LME) \[[@CR18]\] were appropriate. Package "lme4" (version 0.999375-33) available in R was used to fit LME. Package "multcomp" (version 1.1--7) was used to obtain family-wise confidence intervals for the final model preserving the overall type I error for multiple comparisons \[[@CR19]\]. Daily laboratory measurements were averaged if there was more than one measurement per day. Missing values were substituted by last observation carried forward. For display of daily mean within groups, a bootstrapped non-parametric 95% confidence interval is provided \[[@CR20]\]. Laboratory measurements at day 20 were also compared by Mann--Whitney *U* test.

Kaplan--Meier method was used to estimate overall patient and graft survival. Differences between groups were analyzed by log-rank test.

Results {#Sec6}
=======

Overall median follow-up was 25.5 months (IQR 12.5--74.75). Both groups were comparable in terms of age, sex, body mass index, Child-Pugh score, and diagnosis (Table [1](#Tab1){ref-type="table"}). Preoperative transaminases were significantly higher in the experimental group, whereas prothrombin time and total bilirubin were not different. Patients in the experimental group had shorter, warm ischemia time but were not different concerning cold ischemia time, anhepatic time, surgery time, and graft weight ratio. Table 1Baseline and perioperative characteristicsGroupControl (*N* = 7)Experimental (*N* = 15)*P* valueDemographic featuresAge (yr)52 (43.5--55)45 (38.5--53)0.3Female sex1 (14)5 (33)0.6Body mass index (kg/m2)25.5 (22.1--26.6)24.6 (22.75--25.95)0.8Diagnosis:0.8• Cancer3 (43)3 (20)• Alcoholic liver disease1 (14)4 (27)• Chronic viral hepatitis1 (14)4 (27)• Other2 (29)4 (27)Child-Pugh score:0.6• A2 (29)6 (40)• B2 (29)1 (7)• C3 (43)8 (53)Preoperative laboratoryProthombin time (sec)9.2 (9--9.7)9.3 (9--10)0.7Bilirubine (mg/dl)1.5 (0.95--2.25)2.7 (1.3--5.35)0.4AST (U/l)19 (8--26.5)32 (26--110)0.02ALT (U/l)14 (8.75--21)36 (20--100)0.03Perioperative characteristicsCold ischemia time (min)225 (185.5--232)198 (136.5--268)0.8Warm ischemia time (min)24 (18.5--24)18 (14--21)0.06Anhepatic time (min)54 (51.5--58)65 (55--86.5)0.2Surgery time (min)565 (467.5--666.5)530 (457.5--612.5)0.8Graft-weight ratio (%)1.08 (0.94--1.38)0.9 (0.82--1.11)0.23Continuous variables are given in median (interquartile range); discrete variables are given in count (percent in group). *P* values were derived from test statistics of Mann--Whitney *U* test or Fisher\'s exact test for continuous and discrete variables, respectively

Portal vein pressure {#Sec7}
--------------------

Before hepatectomy, recipients had a median PVP of 14.5 mmHg (IQR 13.25--16), and there was no significant differences between experimental and control group (*p* value = 0.98; see Fig. [4a](#Fig4){ref-type="fig"}). After implantation of the graft, there is a significant difference of PVP between both groups (*p* value \< 0.001), although CVP is not different (*p* = 0.43). If we subtract CVP from PVP, we can still see a significant correlation between treatment group and PVP (*p* value = 0.004). Concerning the preoperative PVP, we can see an increase of 3.6 mmHg (*p* value \< 0.001, CI 1.7--5.4) in the control group, whereas PVP decreases in the experimental group by 4.9 mmHg (*p* value \< 0.001, CI −7.2 to −2.6; Fig. [4b](#Fig4){ref-type="fig"}). Fig. 4Boxplot of portal vein pressure (PVP) before and after implantation of the graft (**a**). PVP before implantation is not different (*p* value = 0.98), whereas PVP after implantation of the graft is significantly lower in the experimental group (*p* value \< 0.001). **b** Shows PVP before and after implantation of the graft within groups and for every single patient. Overall, PVP increases in the control group by 3.6 mmHg (*p* value \< 0.001, CI 1.7--5.4), whereas there is a decrease by 4.9 mmHg (*p* value \< 0.001, CI −7.2 to −2.6) in the experimental group

Laboratory measurements {#Sec8}
-----------------------

Daily measurements of liver function tests show significantly lower bilirubinemia in patients that did receive posterior cavoplasty (*p* value = 0.01 in LME model). AST and ALT were also lower in the experimental group, but this did not reach statistical significance (*p* value = 0.091 and 0.078 for AST and ALT, respectively; Fig. [5](#Fig5){ref-type="fig"}). We did not observe differences for PT (*p* value 0.525) and GGT (*p* value = 0.237). Fig. 5Time course of laboratory measurements summarized within groups (mean and bootstrapped nonparametric 95% confidence intervals for the estimate). *ALT* alanine aminotransferase; *PT* prothrombin time

Clinical outcome {#Sec9}
----------------

We did not observe primary nonfunction or acute rejection, but within the study period, one patient died with functioning graft due to infectious complications, one patient was re-transplanted on POD 5 in the control group due to severe graft congestion and one patient in the experimental group due to hepatic artery thrombosis with substantial graft necrosis on the 11th POD. We observed three SFSS in the control group (43%, CI 12--80) and two SFSS in the experimental group (13%, CI 2--42); the difference being without statistical significance (*p*-value = 0.32). SFSS was treated by re-transplantation (one case) or symptomatic therapy (all other cases) and resolved in all patients after 3--6 weeks. We also did not observe significant differences in complications, in-hospital morbidity (*p* value = 0.60 and 0.55, respectively), and length of hospital stay (median 35 days, IQR 25--49). Kaplan--Meier estimates of overall patient survival (Fig. [6](#Fig6){ref-type="fig"}) are 77% at 1 year (CI 62--97), 58% at 3 years (CI 40--83), and 52% at 5 years (CI 34--80). Log-rank test does not show significant differences in patient or graft survival (*p* value = 0.76 and 0.43, respectively). In some patients, computed tomography (CT) was acquired for follow-up at 6 months or later, and these did not show significant stenosis at the anastomosis region in any of the patients of both groups. Fig. 6Kaplan--Meier estimate of overall patient survival by study group. Log-rank test does not show significant differences between control group (*red*) and experimental group (*blue*, *p* value = 0.76)

Discussion {#Sec10}
==========

One of the key features of SFSS is hyperdynamic portal inflow and portal hypertension. Consequently, early attempts to avoid SFSS in LDLT aimed at portal decompression \[[@CR1]\]. But more and more, it is recognized that portal decompression may also have deleterious effects on graft function \[[@CR14]\] because liver regeneration is dependent on adequate graft inflow \[[@CR12], [@CR13]\]. Fan and colleagues have also recognized the paramount importance on adequate outflow \[[@CR1]\]. Outflow obstruction may not only aggravate inflow impedance but also increase portal hypertension, and thus mimic SFSS caused by hyperdynamic portal inflow and portal hypertension. Therapeutic strategies to divert portal inflow may backfire in this situation, because they will further reduce portal inflow and may cause a venous portal steal phenomenon \[[@CR14]\]. Although many studies have shown beneficial effects of portal decompression \[[@CR6]--[@CR13]\], it has already been recognized that this strategy is not feasible in all patients receiving partial liver grafts \[[@CR1], [@CR14]\] and should be restricted to patients with increased portal inflow without outflow obstruction.

Conversely, Fan and colleagues have shown that optimizing outflow is one of the mainstays to avoid SFSS and should be attempted in all patients receiving partial liver grafts \[[@CR1]\]. In addition to their elegant surgical technique of anterior cavoplasty, we propose a posterior cavoplasty, which should even be more effective in small grafts. With this new technique, we can show significant decrease of portal vein pressure, and this results in significantly less hyperbilirubinemia and lower rate of SFSS.

There has been much controversy concerning the management of the MHV and its tributaries \[[@CR1]\]. In our center, it is a common policy to leave the MHV with the donor to minimize the donor risk but to reconstruct larger tributaries to the MHV. We decided to also reconstruct smaller tributaries in the control group, which may explain longer warm ischemia time compared to the experimental group. Multivariate analysis did not show any correlation between warm ischemia time and liver function tests, but weaker effects may not be excluded in this small cohort.

Small grafts should benefit from the described method of posterior cavoplasty because the small graft will tilt backwards in the large abdominal cavity (Fig. [2](#Fig2){ref-type="fig"}), and thus, a ridge will form at the posterior rim of the orifice of the RHV possibly even if the rim is incised as Fan proposes \[[@CR1]\]. By means of posterior cavoplasty, the orifice of the RHV is enlarged in the dorsolateral direction, and we may prevent choking of the outflow tract by backwards tilt in the early phase after LDLT. Later on growth of the liver should adjust the functional anastomosis by rectifying the outflow tract. But regeneration is only possible when there is no small-for-size graft injury in the early phase. It might also be possible that in patients with posterior cavoplasty, a stenosis of the outflow tract will develop after growth of the liver, but we did not observe this in any of our patients.

In conclusion, we have shown that in this test-of-concept study, our new method of posterior cavoplasty resulted in significant reduction of PVP and bilirubinemia and a non-significant reduction of SFSS. Therefore, we recommend posterior cavoplasty to avoid venous outflow obstruction and possibly SFSS in small grafts. We are planning to confirm the findings of this feasibility study in a larger cohort of patients.
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